

**ANNEX I**  
**SUMMARY OF PRODUCT CHARACTERISTICS**

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

YURVAC RHD emulsion for injection for rabbits

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each dose of 0.5 ml contains:

### Active substance:

Recombinant RHDV2 virus capsid protein RP  $\geq 0.7$

\* Relative Potency (ELISA test)

### Adjuvant:

Light mineral oil 104.125 mg

### Excipients:

Qualitative composition of excipients and other constituents	Quantitative composition if that information is essential for proper administration of the veterinary medicinal product
Polysorbate 80	0.03 g
Sorbitan mono-oleate	
Sodium chloride	
Potassium chloride	
Disodium phosphate dodecahydrate	
Potassium dihydrogen phosphate	
Water for injections	

White homogeneous emulsion.

## 3. CLINICAL INFORMATION

### 3.1 Target species

Rabbits, including pet (dwarf) rabbits.

### 3.2 Indications for use for each target species

For active immunisation of rabbits from 30 days of age onwards to reduce mortality of rabbit haemorrhagic disease (RHD) caused by classical RHD virus (RHDV) and variant strains (RHDV2), including highly virulent strains.

Onset of immunity: 7 days for RHDV2  
14 days for RHDV

Duration of immunity: 1 year

For passive immunisation against RHDV2 (not demonstrated against highly virulent strains) of the offspring of the vaccinated does for at least 30 days.

### 3.3 Contraindications

Do not use in cases of hypersensitivity to the active substance, to the adjuvant or to any of the excipients.

### 3.4 Special warnings

Vaccinate healthy animals only.

### 3.5 Special precautions for use

Special precautions for safe use in the target species:

Pregnant does should be handled gently to avoid stress and risk of abortion.  
No safety study on the reproductive performance has been conducted in male rabbits (bucks).

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

To the user:

This veterinary medicinal product contains mineral oil. Accidental injection/self-injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given. If you are accidentally injected with this veterinary medicinal product, seek prompt medical advice even if only a very small amount is injected and take the package leaflet with you. If pain persists for more than 12 hours after medical examination, seek medical advice again.

To the physician:

This veterinary medicinal product contains mineral oil. Even if small amounts have been injected, accidental injection with this veterinary medicinal product can cause intense swelling, which may, for example, result in ischaemic necrosis and even the loss of a digit. Expert, PROMPT, surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where there is involvement of finger pulp or tendon.

Special precautions for the protection of the environment:

Not applicable.

### 3.6 Adverse events

Rabbits, including pet (dwarf) rabbits:

Very common (> 1 animal / 10 animals treated):	Elevated temperature <sup>1</sup> Injection site inflammation <sup>2</sup>
Very rare (< 1 animal / 10 000 animals treated, including isolated reports):	Anorexia <sup>3</sup> Intestinal stasis <sup>3</sup>

<sup>1</sup> The highest individual rectal temperature increase was 1.15 °C which returned to normal values 24 hours later.

<sup>2</sup> Inflammation (< 2 cm) at the injection can be observed. These local reactions gradually reduce and disappear without need for treatment.

<sup>3</sup> Transient.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

### **3.7 Use during pregnancy, lactation or lay**

#### Pregnancy and lactation:

Can be used during pregnancy and lactation.

### **3.8 Interaction with other medicinal products and other forms of interaction**

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

### **3.9 Administration routes and dosage**

Subcutaneous use.

#### Primary vaccination:

Administer one dose (0.5 ml) subcutaneously to rabbits from 30 days of age onwards.

#### Revaccination:

Revaccinate annually with one dose (0.5 ml) by subcutaneous injection.

Allow the vaccine to reach room temperature before use.

Shake well before administration.

### **3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)**

No adverse reactions other than those mentioned in section 3.6 were observed after the administration of a 5-fold dose.

### **3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance**

Not applicable.

### **3.12 Withdrawal periods**

Zero days.

## **4. IMMUNOLOGICAL INFORMATION**

### **4.1 ATCvet code:**

ATC vet code: QI08AV.

The vaccine is intended to stimulate active immunity against RHDV and RHDV2 and passive immunity against RHDV2. Passive immunity against highly virulent RHDV2 strain was not tested. The younger are naturally protected against the classical RHD virus.

The active substance of the vaccine is the recombinant RHDV2 capsid protein, which auto-assembles into Virus Like Particles (VLPs).

## **5. PHARMACEUTICAL PARTICULARS**

### **5.1 Major incompatibilities**

Do not mix with any other veterinary medicinal product.

### **5.2 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 1 year.

Shelf life after first opening the immediate packaging: 10 hours.

### **5.3 Special precautions for storage**

Store and transport refrigerated (2 °C – 8 °C).

Do not freeze.

Keep the vial in the outer carton in order to protect from light.

### **5.4 Nature and composition of immediate packaging**

Type I colourless glass vials with 0.5 ml (1 dose) and 5 ml (10 doses).

The vials are closed with a rubber stopper and an aluminium cap.

Type I colourless PET vials with 20 ml (40 doses) and 100 ml (200 doses).

The vials are closed with a rubber stopper and an aluminium cap.

#### Pack sizes:

Cardboard box of 10 glass vials of 1 dose (0.5 ml).

Cardboard box of 1 glass vial of 10 doses (5 ml).

Cardboard box of 1 PET vial of 40 doses (20 ml).

Cardboard box of 1 PET vial of 200 doses (100 ml).

Not all pack sizes may be marketed.

### **5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

## **6. NAME OF THE MARKETING AUTHORISATION HOLDER**

LABORATORIOS HIPRA, S.A.

## **7. MARKETING AUTHORISATION NUMBER(S)**

EU/2/23/298/001

EU/2/23/298/002

EU/2/23/298/003

EU/2/23/298/004

**8. DATE OF FIRST AUTHORISATION**

Date of first authorisation: 11/09/2023

**9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS**

**10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS**

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).

## **ANNEX II**

### **OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**

#### **SPECIFIC PHARMACOVIGILANCE REQUIREMENTS:**

The MAH shall record in the pharmacovigilance database all results and outcomes of the signal management process, including a conclusion on the benefit-risk balance, according to the following frequency: annually.

**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**CARDBOARD BOX**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

YURVAC RHD emulsion for injection for rabbits

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each dose of 0.5 ml contains:

Recombinant RHDV2 virus capsid protein                      RP  $\geq 0.7$

\* Relative Potency (ELISA test)

**3. PACKAGE SIZE**

10 x 1 dose (0.5 ml).

10 doses (5 ml).

40 doses (20 ml).

200 doses (100 ml).

**4. TARGET SPECIES**

Rabbits, including pet (dwarf) rabbits.

**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

Subcutaneous use.

**7. WITHDRAWAL PERIODS**

Withdrawal period: Zero days.

**8. EXPIRY DATE**

Exp. {mm/yyyy}

Once broached use within 10 hours.

**9. SPECIAL STORAGE PRECAUTIONS**

Store and transport refrigerated.  
Do not freeze.  
Keep the vial in the outer carton in order to protect from light.

**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

**11. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**13. NAME OF THE MARKETING AUTHORISATION HOLDER**

LABORATORIOS HIPRA, S.A.

**14. MARKETING AUTHORISATION NUMBERS**

EU/2/23/298/001 (1 dose)  
EU/2/23/298/002 (10 doses)  
EU/2/23/298/003 (40 doses)  
EU/2/23/298/004 (200 doses)

**15. BATCH NUMBER**

Lot {number}

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE**

**VIAL OF 200 DOSES**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

YURVAC RHD emulsion for injection for rabbits

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each dose of 0.5 ml contains:

Recombinant RHDV2 virus capsid protein                      RP  $\geq 0.7$   
\* Relative Potency (ELISA test)

**3. TARGET SPECIES**

Rabbits, including pet (dwarf) rabbits.

**4. ROUTES OF ADMINISTRATION**

Subcutaneous use.  
Read the package leaflet before use.

**5. WITHDRAWAL PERIODS**

Withdrawal period: Zero days.

**6. EXPIRY DATE**

Exp. {mm/yyyy}

Once broached use within 10 hours.

**7. SPECIAL STORAGE PRECAUTIONS**

Store and transport refrigerated.  
Do not freeze.  
Keep the vial in the outer carton in order to protect from light.

**8. NAME OF THE MARKETING AUTHORISATION HOLDER**

LABORATORIOS HIPRA, S.A.

**9. BATCH NUMBER**

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**  
**VIAL OF 1 DOSE, 10 DOSES AND 40 DOSES**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

YURVAC RHD emulsion for injection for rabbits

**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

Each dose of 0.5 ml contains:

Recombinant RHDV2 virus capsid protein                      RP \*  $\geq 0.7$   
\* Relative Potency (ELISA test)

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}  
Once broached use within 10 hours.

**B. PACKAGE LEAFLET**

## PACKAGE LEAFLET

### 1. Name of the veterinary medicinal product

YURVAC RHD emulsion for injection for rabbits

### 2. Composition

Each dose of 0.5 ml contains:

**Active substance:** Recombinant RHDV2 virus capsid protein                      RP \*  $\geq 0.7$   
\* Relative Potency (ELISA test)

**Adjuvant:** Light mineral oil    104.125 mg

White homogeneous emulsion.

### 3. Target species

Rabbits, including pet (dwarf) rabbits.

### 4. Indications for use

For active immunisation of rabbits from 30 days of age onwards to reduce mortality of rabbit haemorrhagic disease (RHD) caused by classical RHD virus (RHDV) and variant strains (RHDV2), including highly virulent strains.

Onset of immunity: 7 days for RHDV2  
14 days for RHDV

Duration of immunity: 1 year

For passive immunisation against RHDV2 (not demonstrated against highly virulent strains) of the offspring of the vaccinated does for at least 30 days.

### 5. Contraindications

Do not use in cases of hypersensitivity to the active substance, to the adjuvant or to any of the excipients.

### 6. Special warnings

Special warnings:

Vaccinate healthy animals only.

Special precautions for safe use in the target species:

Pregnant does should be handled gently to avoid stress and risk of abortion.

No safety study on the reproductive performance has been conducted in male rabbits (bucks).

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

To the user:

This veterinary medicinal product contains mineral oil. Accidental injection/self-injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given. If you are accidentally injected with this veterinary medicinal product, seek prompt medical advice even if only a very small amount is injected and take the package leaflet with you. If pain persists for more than 12 hours after medical examination, seek medical advice again.

To the physician:

This veterinary medicinal product contains mineral oil. Even if small amounts have been injected, accidental injection with this veterinary medicinal product can cause intense swelling, which may, for example, result in ischaemic necrosis and even the loss of a digit. Expert, PROMPT, surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where there is involvement of finger pulp or tendon.

Special precautions for the protection of the environment:

Not applicable.

Pregnancy and lactation:

Can be used during pregnancy and lactation.

Interaction with other medicinal products and other forms of interaction:

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

Overdose:

No adverse reactions other than those mentioned in “adverse events” section were observed after the administration of a 5-fold dose.

Special restrictions for use and special conditions for use:

Not applicable.

Major incompatibilities:

Do not mix with any other veterinary medicinal product.

## **7. Adverse events**

Rabbits, including pet (dwarf) rabbits:

Very common (> 1 animal / 10 animals treated):	Elevated temperature <sup>1</sup> Injection site inflammation <sup>2</sup>
Very rare (< 1 animal / 10 000 animals treated, including isolated reports):	Anorexia <sup>3</sup> Intestinal stasis <sup>3</sup>

<sup>1</sup> The highest individual rectal temperature increase was 1.15 °C which returned to normal values 24 hours later.

<sup>2</sup> Inflammation (< 2 cm) at the injection can be observed. These local reactions gradually reduce and disappear without need for treatment.

<sup>3</sup> Transient.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. If you notice any side effects, even those not already listed in this package leaflet,

or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system: [{national system details}](#).

## **8. Dosage for each species, routes and method of administration**

Subcutaneous use.

Primary vaccination:

Administer one dose (0.5 ml) subcutaneously to rabbits from 30 days of age onwards.

Revaccination:

Revaccinate annually with one dose (0.5 ml) by subcutaneous injection.

## **9. Advice on correct administration**

Allow the vaccine to reach room temperature before use.

Shake well before use.

## **10. Withdrawal periods**

Zero days.

## **11. Special storage precautions**

Keep out of the sight and reach of children.

Store and transport refrigerated (2 °C – 8 °C).

Do not freeze.

Keep the vial in the outer carton in order to protect from light.

Do not use this veterinary medicinal product after the expiry date, which is stated on the label and the carton.

Shelf life after first opening the immediate packaging: 10 hours.

## **12. Special precautions for disposal**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

**13. Classification of veterinary medicinal products**

Veterinary medicinal product subject to prescription.

**14. Marketing authorisation numbers and pack sizes**

EU/2/23/298/001-004

Pack sizes:

Cardboard box of 10 glass vials of 1 dose (0.5 ml).  
Cardboard box of 1 glass vial of 10 doses (5 ml).  
Cardboard box of 1 PET vial of 40 doses (20 ml).  
Cardboard box of 1 PET vial of 200 doses (100 ml).

Not all pack sizes may be marketed.

**15. Date on which the package leaflet was last revised**

{MM/YYYY}

Detailed information on this veterinary medicinal product is available in the Union Product Database (<https://medicines.health.europa.eu/veterinary>).

**16. Contact details**

Marketing authorisation holder and manufacturer responsible for batch release and contact details to report suspected adverse reactions:

LABORATORIOS HIPRA, S.A.  
Avda. La Selva, 135  
17170 Amer (Girona) SPAIN Tel. +34 972 43 06 60

Local representatives and contact details to report suspected adverse reactions:

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

**België/Belgique/Belgien**

HIPRA BENELUX NV  
Nieuwewandeling 62  
9000 Gent  
BELGIË  
Tel: +32 09 2964464

**Република България**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
ИСПАНИЯ  
Тел: +34 972 43 06 60

**Česká republika**

HIPRA SLOVENSKO, s.r.o.  
Zochova 5,  
811 03 Bratislava,  
SLOVENSKO  
Tel: +421 02 32 335 223

**Danmark**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
SPANIEN  
Tel: +34 972 43 06 60

**Deutschland**

HIPRA DEUTSCHLAND GmbH  
Am Wehrhahn 28-30  
40211 Düsseldorf  
DEUTSCHLAND  
Tel: +49 211 698236 – 0

**Eesti**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
HISPAANIA  
Tel: +34 972 43 06 60

**Ελλάδα**

HIPRA ΕΛΛΑΣ Α.Ε.  
Λεωφ. Αθηνών 80 & Μηριόνη 2-4,  
104 41 Κολωνός - ΑΘΗΝΑ - ΕΛΛΑΣ  
Τηλ: +30 210 4978660

**Lietuva**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
ISPANIJA  
Tel: +34 972 43 06 60

**Luxembourg/Luxemburg**

HIPRA BENELUX NV  
Nieuwewandeling 62  
9000 Gent  
BELGIQUE  
Tel: +32 09 2964464

**Magyarország**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
SPANYOLORSZÁG  
Tel: +34 972 43 06 60

**Malta**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
SPANJA  
Tel: +34 972 43 06 60

**Nederland**

HIPRA BENELUX NV  
Nieuwewandeling 62  
9000 Gent  
BELGIË  
Tel: +32 09 2964464

**Norge**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
SPANIA  
Tlf: +34 972 43 06 60

**Österreich**

HIPRA DEUTSCHLAND GmbH  
Am Wehrhahn 28-30  
40211 Düsseldorf  
DEUTSCHLAND  
Tel: +49 211 698236 – 0

**España**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
ESPAÑA  
Tel: +34 972 43 06 60

**France**

HIPRA FRANCE  
7 rue Roland Garros, Batiment H  
44700 - Orvault -  
FRANCE  
Tél: +33 02 51 80 77 91

**Hrvatska**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
ŠPANJOLSKA  
Tel: +34 972 43 06 60

**Ireland**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
SPAIN  
Tel: +34 972 43 06 60

**Ísland**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
SPÁNN  
Sími: +34 972 43 06 60

**Italia**

Hipra Italia S.r.l.  
Enrico Mattei, 2  
25030 Coccaglio (BS)  
ITALIA  
Tel: +39 030 7241821

**Κύπρος**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
ΙΣΠΑΝΙΑ  
Τηλ: +34 972 43 06 60

**Latvija**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
SPĀNIJA  
Tel. +34 972 43 06 60

**Polska**

HIPRA POLSKA Sp.z.o.o.  
Ul. Wincentego Rzymowskiego 31  
02-697 Warszawa - POLSKA  
Tel: +48 22 642 33 06

**Portugal**

ARBUSET, Produtos Farmacêuticos e Sanitários  
De Uso Animal, Lda  
Portela de Mafra e Fontainha - Abrunheira  
2665 – 191 Malveira - PORTUGAL  
Tel:+351 219 663 450

**România**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
SPANIA  
Tel: +34 972 43 06 60

**Slovenija**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
ŠPANIJA  
Tel: +34 972 43 06 60

**Slovenská republika**

HIPRA SLOVENSKO, s.r.o.  
Zochova 5,  
811 03 Bratislava,  
SLOVENSKO  
Tel: +421 02 32 335 223

**Suomi/Finland**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
ESPANJA  
Puh/Tel: +34 972 43 06 60

**Sverige**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
SPANIEN  
Tel. +34 972 43 06 60

**United Kingdom (Northern Ireland)**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
SPAIN  
Tel: +34 972 43 06 60